During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Monitoring and analyzing gut microbes may help predict how myeloma patients will respond to CAR T-cell therapy, research ...

Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...